---

Psoriasis: Research

Answer

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).

The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.

UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.

In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.

- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.

- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma

Details of UKRI and NIHR funding on specific areas is provided in the table below:

	NIHR	UKRI
Acne	NIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.	UKRI did not commit any specific funding for acne research in 2023-24.
Alopecia	NIHR did not allocate any funds for research concerning alopecia research during 2023-24	UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.
Psoriasis	NIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.	UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .
Pemphigus	NIHR did not allocate any funds for research concerning pemphigus research during 2023-24	UKRI did not commit any specific funding for pemphigus research in 2023-24.
Atopic Dermatitis	NIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.	UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.
Epidermolysis Bullosa	NIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24	UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.
Hidradenitis Suppurativa	NIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24	UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.
Scleroderma	NIHR allocated £155,575 for research concerning scleroderma research in 2023-24.	UKRI did not commit any specific funding for scleroderma research in 2023-24.
Rosacea	NIHR did not allocate any funds concerning rosacea research during 2023-24	UKRI did not commit any specific funding for rosacea research in 2023-24.
Vitiligo	NIHR did not allocate any funds for research concerning vitiligo research during 2023-24	UKRI did not commit any specific funding for vitiligo research in 2023-24.
Basal Cell Carcinoma	NIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24	UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.
Squamous Cell Carcinoma	NIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24	UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.
Melanoma	NIHR allocated £1,167,536 for research concerning melanoma research in 2023-24	UKRI have committed £176,114 for melanoma research between March 24 and August 25.
Actinic Keratosis	NIHR did not allocate any funds concerning actinic keratosis research during 2023-24	UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Secondary information

Type

Written question

Reference

31628

Session

2024-26

Grouped for answer

Yes

Subjects

Expenditure Research Psoriasis

Contains statistics

Yes

Link

View this Written question on www.parliament.uk